Benchmark Maintains Buy, $4.50 PT on RTI Biologics

Benchmark remains Buy-rated with a $4.50 target price on RTI Biologics RTIX as the company's conservative outlook presents a buying opportunity. Benchmark says, "Results in Q4 were not supported by stocking shipments, which we believe bodes well for potential stocking upside in Q1 and future periods. Initial MAPC sales are anticipated in 2H12 but significant revenue is not anticipated until 2013 when the product can be supported by further human post-marketing clinical studies. We anticipate substantial additional information regarding MAPC and other pipeline products at RTI's investor presentation on February 7. We anticipate this event should be a favorable catalyst for RTIX shares because it is an opportunity to highlight RTI's substantial new-product growth opportunities." RTIX closed at $3.45 a share yesterday.